Contact Us

9 Years, One Biomarker Panel, and a Vision for Equitable Stroke Care

Upfront_World_Stroke_Day

9 Years, One Biomarker Panel, and a Vision for Equitable Stroke Care

On World Stroke Day, the global medical community unites to address one of healthcare’s most time-critical emergencies. For me, this year marks a milestone that is deeply personal: European regulatory approval for LVOne, our prehospital stroke diagnostic device.

This is my first regulatory approval as Chief Scientific Officer, and I am immensely proud. Nine years ago, we began as a basic research project, searching for blood-based stroke biomarkers in a field where decades of effort had failed to deliver a product to patients. Yet our team navigated every stage – from discovery and clinical validation through prototyping and optimisation to regulatory clearance. Leading every step of that translational pathway has been a privilege. But the work that matters most starts now: turning approval into real-world care transformation. Europe is only the beginning.

Bridging the Gap in European Stroke Care

European stroke care is among the best in the world, yet most patients still lack direct access to mechanical thrombectomy. Building more capacity alone cannot solve this issue; thrombectomy is a highly specialised procedure that will always remain concentrated in centralised hubs.

The primary gap lies in early identification before patients reach the hospital. When stroke strikes, rapid, accurate triage dictates functional recovery. We developed LVOne to integrate seamlessly alongside existing prehospital pathways, so that patients can be triaged wherever their stroke occurs.

The Science Behind LVOne

When we launched our initial discovery study in 2018, it was clear that accurate prehospital triage required combining multiple key biological data points. Clinical stroke symptoms are non-specific, and severe symptoms alone cannot distinguish between stroke subtypes.

LVOne was developed with a deliberately simple, dual-action panel designed to address this diagnostic challenge at first contact:

  • Rule in severe ischaemic stroke: Rapidly identifying patients most likely to have a large vessel occlusion (LVO).
  • Rule out haemorrhagic stroke: Safely eliminating the primary diagnostic mimic, as brain bleeds present with identical severity.

This targeted combination has proven remarkably effective in prehospital settings, providing emergency personnel with immediate insight before hospital arrival.

Looking Ahead

Securing European regulatory clearance proves that blood-based stroke triage is no longer just a research concept – it is a practical clinical solution. As we mark World Stroke Day, our focus shifts entirely from regulatory success to frontline implementation. Delivering stroke care should not depend on geography, and with LVOne, we are taking a definitive step towards making universal prehospital stroke triage a global reality.

Leave a Comment

Recent Posts

patient care

Innovation Must Begin and End with the Patient

Every year on World Stroke Day, the global medical community rallies around a stark, unavoidable rea
Read More
BE-16x9-26-S46

Upfront diagnostics named to the 2026 BE100

We’re grateful to be recognised among the 2026 BE100—and deeply thankful to the committed team w
Read More
Upfront Diagnostics Partnership

Upfront Diagnostics & Vingmed Group Partner to Bring Stroke Tech to Nordics

We are pleased to announce a strategic partnership between Upfront Diagnostics, a UK-based MedTech c
Read More